| hsa05167 |
Kaposi sarcoma-associated herpesvirus infection |
3.48E-08 |
PTGS2, MAPK14, CALM1, STAT1, CCND1, MAPK1, NFKBIA, CASP8, IFNGR1, E2F2 |
| hsa05145 |
Toxoplasmosis |
1.27E-07 |
MAPK14, STAT1, ALOX5, BCL2L1, MAPK1, NFKBIA, CASP8, IFNGR1 |
| hsa05140 |
Leishmaniasis |
1.92E-07 |
PTGS2, MAPK14, STAT1, MAPK1, NFKBIA, PRKCB, IFNGR1 |
| hsa05163 |
Human cytomegalovirus infection |
6.88E-07 |
PTGS2, MAPK14, CALM1, CCND1, MAPK1, NFKBIA, CASP8, PRKCB, E2F2 |
| hsa04933 |
AGE-RAGE signaling pathway in diabetic complications |
6.88E-07 |
MAPK14, STAT1, CCND1, MAPK1, PRKCB, THBD, COL1A1 |
| hsa05161 |
Hepatitis B |
6.88E-07 |
MAPK14, STAT1, MMP9, MAPK1, NFKBIA, CASP8, PRKCB, E2F2 |
| hsa04625 |
C-type lectin receptor signaling pathway |
6.88E-07 |
PTGS2, MAPK14, CALM1, STAT1, MAPK1, NFKBIA, CASP8 |
| hsa04657 |
IL-17 signaling pathway |
9.38E-06 |
PTGS2, MAPK14, MMP9, MAPK1, NFKBIA, CASP8 |
| hsa04668 |
TNF signaling pathway |
2.36E-05 |
PTGS2, MAPK14, MMP9, MAPK1, NFKBIA, CASP8 |
| hsa05170 |
Human immunodeficiency virus 1 infection |
5.18E-05 |
MAPK14, CALM1, BCL2L1, MAPK1, NFKBIA, CASP8, PRKCB |
